Rebiotix Receives Breakthrough Therapy Designation for RBX2660 for the Treatment of Recurrent Clostridium difficile Infection.
- Published in:
- Clinical Infectious Diseases, 2016, v. 62, n. 1, p. i, doi. 10.1093/cid/civ934
- Publication type:
- Article
Works matching DE "REBIOTIX Inc."
Results: 2
1
2
Microbial wealth.
- Published in:
- Chemistry & Industry, 2014, v. 78, n. 6, p. 20, doi. 10.1002/cind.786_6.x
- Publication type:
- Article